{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
INN:tarcocimab tedromer [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03226444: Phase 1/Phase 2 Interventional Completed Primary Sjögren Syndrome
(2017)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03145909: Phase 1 Interventional Terminated Advanced Solid Tumors Cancer
(2017)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02725476: Phase 2 Interventional Completed IgG4-RD
(2016)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04305041: Phase 1/Phase 2 Interventional Active, not recruiting Melanoma
(2020)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00019383: Phase 2 Interventional Completed Melanoma (Skin)
(1998)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03932110: Not Applicable Interventional Completed Psoriasis Vulgaris
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04701983: Phase 3 Interventional Active, not recruiting Chronic Obstructive Pulmonary Disease
(2020)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04658862: Phase 3 Interventional Active, not recruiting Urinary Bladder Neoplasms
(2020)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03186677: Phase 1 Interventional Completed Hemophilia B
(2017)
Source URL:
Class:
PROTEIN
